rmdopen.bmj4d
Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
1 Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital, Le Kremlin-Bicêtre, France 2 INSERM U1184, Center for Immunology of Viral Infections and Autoimmune ...
rmdopen.bmj4d
Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
Objectives To evaluate the sensitivity to change of ultrasound structural gout lesions, as defined by the Outcome Measures in Rheumatology (OMERACT) ultrasound group, in patients with gout during ...
rmdopen.bmj8d
Systemic disease activity measured with ESSDAI varies largely over 5 years in a prospective, longitudinal cohort of patients with Sjögren’s disease
Objectives The objectives are to evaluate variation in systemic disease activity (European Alliance of Associations For Rheumatology (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI)) over ...
rmdopen.bmj10d
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use ...
rmdopen.bmj12d
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature
Objective To assess whether the polymyalgia rheumatica (PMR)-like syndrome reported as an immune related adverse event (irAE) from checkpoint inhibitor therapy is consistent with the 2012 European ...
rmdopen.bmj17d
Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren’s disease
Introduction The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren’s disease (SjD) can be suspected from the results of two phase II clinical trials but has not been ...
rmdopen.bmj18d
Mixed connective tissue disease: state of the art on clinical practice guidelines
Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic ...
rmdopen.bmj21d
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
Objective To evaluate the magnitude of response to secukinumab treatment over 3 years in patients with ankylosing spondylitis (AS) grouped by baseline C-reactive protein (CRP) levels in a pooled study ...
rmdopen.bmj21d
Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis
Objective We aimed to analyse the association between infections and the subsequent risk of giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR) by a systematic review and a meta-analysis of ...
rmdopen.bmj21d
Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
Psoriatic arthritis (PsA) is a complex, multiform and chronic inflammatory disease characterised by the association of arthritis and psoriasis combined with other related conditions and comorbidities.
rmdopen.bmj25d
Ehlers-Danlos syndromes: state of the art on clinical practice guidelines
Objective To report the effort of the European Reference Network for Rare and Complex CONnective tissue and musculoskeletal diseases NETwork working group on Ehlers-Danlos syndromes (EDS) and related ...
rmdopen.bmj25d
Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective
Objective To evaluate the performance of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) criteria in terms of earlier ...